Welcome to our dedicated page for 23Andme Holding news (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23Andme Holding stock.
23andMe Holding Co. reported developments tied to its human genetics, consumer health, and research businesses, including new 23andMe+ Premium genetic reports, lab-test offerings, and Discover23 research access for biopharma collaborators. Company updates also covered its proprietary genetic and health-information database, consented research participation, and privacy policies governing customer data.
Recent corporate news focused on liquidity, discontinued therapeutics operations, strategic alternatives, board and leadership changes, and Chapter 11 proceedings involving a court-supervised asset sale process. These updates frame the company’s transition from an operating consumer genetics business into a restructuring and corporate-status story.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.